Wednesday, August 09, 2006


EyeWorld Magazine: August�2006

This article explains what we all probably already know. 40% of patients on a prostaglandin analogue will need adjunctive therapy, and that a topical carbonic anhydrase inhibitor is more effective than an alpha-agonist (brimonodine or Alphagan-P) as an adjunct. Also brimonodine's effect wears off over time and does not display as flat a diurnal curve as Azopt (or Trusopt).

1 comment:

  1. Kevin,
    Ironically, the Allergan rep. just showed me a report yesterday concluding that Alphagan-P is the best adjunctive therapy for glaucoma. I forget which source it was from.
    Sometimes it's hard to know which way to go when there are conflicting studies!


Leave a Comment or Question: